United States First Circuit
In re Nexium Antitrust Litigation, 14-1521
In this class action involving sale of a prescription heartburn drug, plaintiffs assert that, but for defendants anti-competitive conduct, a generic version would have been available several years earlier, lowering the price through competition. Plaintiffs claimed damages under various state antitrust and consumer protection laws and sought class certification for a class of third-party payers, including the named plaintiffs and individual consumers. The judgment of the district court certifying the class is affirmed, where: 1) class certification is permissible even if the class includes a de minimis number of uninjured parties; and 2) the district court did not abuse its discretion by certifying the class here and determining that, at the certification stage, it had not been shown that future proceedings would not be manageable consistent with defendants' Seventh Amendment and due process rights.
Appellate Information
- Decided 01/22/2015
- Published 01/22/2015
Judges
- Dyk
Court
- United States First Circuit